Chapter 15: Recurrent or persistent primary hyperparathyroidism, parathyromatosis
Annales d'Endocrinologie · 2025-02 · 86 (1) · 101704
DOI: 10.1016/j.ando.2025.101704 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annales d'Endocrinologie, 2025-02. Verfasst von Miriam Ladsous und 4 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology, Diabetology, Metabolism and Nutrition Department, CHU de Lille, hôpital Claude-Huriez, 59000 Lille, France. Electronic address: miriam…. Hauptthemen laut MEDLINE: Hyperparathyroidism, Primary. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Persistent primary hyperparathyroidism is defined as the persistence or recurrence of hypercalcemia within 6 months of parathyroid surgery. Recurrent primary hyperparathyroidism is defined as the recurrence of primary hyperparathyroidism more than 6 months after an initially curative parathyroidectomy. In these situations, it is essential to rule out differential diagnoses, and in particular secondary hyperparathyroidism and familial hypocalciuric hypercalcemia. Failure to remove the pathological parathyroid gland or glands during initial surgery for primary hyperparathyroidism is the most common situation in non-expert centers. In other situations, genetically determined multi-glandular primary hyperparathyroidism must be screened for. More rarely, a second sporadic adenoma is identified, or, exceptionally, a parathyroid carcinoma or parathyromatosis. Effective morphological evaluation, combining a morphological and functional imaging, is essential prior to any new parathyroid surgery. The indications for surgery must be discussed in a multidisciplinary team, assessing the risk/benefit ratio, since the risk of surgical complications is higher. Revision surgery should be performed using a suitable approach, after laryngoscopy, in an expert center, ideally with intraoperative PTH measurement and recurrent nerve neuromonitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Endocrinology, Diabetology, Metabolism and Nutrition Department, CHU de Lille, hôpital Claude-Huriez, 59000 Lille, France. Electronic address: miriam.ladsous@chu-lille.fr.
- Digestive and Endocrine Surgery Department, CHU de Reims, hôpital Robert-Debré, 51100 Reims, France. Electronic address: sdeguelte@chu-reims.fr.
- Department of Nuclear Medicine, CHU de Bordeaux, 33000 Bordeaux, France. Electronic address: elif.hindie@chu-bordeaux.fr.
- Department of General and Endocrine Surgery, CHU de Lille, hôpital Claude-Huriez, 59000 Lille, France. Electronic address: robert.caiazzo@chu-lille.fr.
- Department of Endocrinology Diabetes Nutrition, HU de Reims, hôpital Robert-Debré, 51100 Reims, France. Electronic address: bdelemer@chu-reims.fr.
Zitieren
APA
Ladsous, M., Deguelte, S., Hindié, E., Caiazzo, R., & Delemer, B. (2025). Chapter 15: Recurrent or persistent primary hyperparathyroidism, parathyromatosis. Annales d'Endocrinologie, 86(1), 101704. https://doi.org/10.1016/j.ando.2025.101704
Vancouver
Ladsous M, Deguelte S, Hindié E, Caiazzo R, Delemer B. Chapter 15: Recurrent or persistent primary hyperparathyroidism, parathyromatosis. Annales d'Endocrinologie. 2025;86(1):101704. doi:10.1016/j.ando.2025.101704
BibTeX
@article{Ladsous2025,
author = {Ladsous, Miriam and Deguelte, Sophie and Hindié, Elif and Caiazzo, Robert and Delemer, Brigitte},
title = {Chapter 15: Recurrent or persistent primary hyperparathyroidism, parathyromatosis},
journal = {Annales d'Endocrinologie},
year = {2025},
volume = {86},
number = {1},
pages = {101704},
doi = {10.1016/j.ando.2025.101704}
}
EUVIMED